Aura Biosciences, Inc. (AURA) Financial Analysis & Valuation | Quarter Chart
Aura Biosciences, Inc. (AURA)
AURAPrice: $6.36
Fair Value: 🔒
🔒score
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment... more
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. ... more
Description
Shares
| Market Cap | $403.88M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Elisabet de los Pinos |
| IPO Date | 2021-10-29 | CAGR | — |
| Employees | 106 | Website | www.aurabiosciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AURA chart loading...
Fundamentals
Technicals
| Enterprise Value | $377.69M | P/E Ratio | -2.74 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 2.68 |
| P/CF Ratio | -4.75 | P/FCF Ratio | -4.55 |
| EPS | $-1.95 | EPS Growth 1Y | 12.14% |
| EPS Growth 3Y | 4.3% | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.7% | ROA | -0.56% |
| ROCE | -0.66% | Current Ratio | 9.04 |
| Quick Ratio | 9.04 | Cash Ratio | 2.53 |
| Debt/Equity | 0.11 | Interest Coverage | — |
| Altman Z Score | 3.21 | Piotroski Score | 1 |